The Claim
Among adults taking rosuvastatin, carriers of the ABCG2 rs2231142 variant exhibit a threefold higher incidence of liver enzyme elevation compared to non-carriers, with this effect being more pronounced in East Asian individuals.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Adults taking rosuvastatin who carry the ABCG2 rs2231142 genetic variant have three times the rate of liver enzyme elevation as those without the variant, especially among people of East Asian ancestry.
See the scientific wording
Among adults taking rosuvastatin, carriers of the ABCG2 rs2231142 variant have a threefold increased risk of liver enzyme elevation, particularly among East Asian individuals, indicating that this genetic variant interacts with ethnicity to heighten hepatotoxicity risk.
A genetic change in the ABCG2 gene makes a liver protein less able to push rosuvastatin out of liver cells. This causes the drug to build up inside the cells, damaging the energy-producing parts of the cells. The damaged cells leak liver enzymes into the blood, which shows up as elevated liver enzyme levels in blood tests.
What the research says
1 studyPeople taking rosuvastatin who have a specific gene variant called ABCG2 rs2231142 are about three times more likely to have liver enzyme levels rise, especially if they are of East Asian descent — and this study found exactly that.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.